EI
MRTX

EAM Investors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

EAM Investors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,552
Closed -$2.54M – 467
2020
Q4 		$2.54M Sell
11,552
-364
-3% -$78.7K 0.42% 60
2020
Q3 		$1.98M Buy
+11,916
New +$1.63M 0.47% 59
2020
Q1 		– Sell
-11,521
Closed -$1.49M – 306
2019
Q4 		$1.49M Sell
11,521
-6,963
-38% -$672K 0.33% 145
2019
Q3 		$1.44M Sell
18,484
-16,675
-47% -$1.56M 0.38% 129
2019
Q2 		$3.62M Sell
35,159
-4,556
-11% -$355K 0.89% 10
2019
Q1 		$2.91M Buy
+39,715
New +$2.7M 0.71% 28
2018
Q4 		– Sell
-68,981
Closed -$3.25M – 337
2018
Q3 		$3.25M Sell
68,981
-30,675
-31% -$1.71M 0.48% 90
2018
Q2 		$4.91M Buy
99,656
+38,626
+63% +$1.46M 0.77% 6
2018
Q1 		$1.87M Buy
61,030
+26,212
+75% +$728K 0.31% 144
2017
Q4 		$635K Buy
+34,818
New +$540K 0.11% 263
2016
Q1 		– Sell
-29,838
Closed -$943K – 356
2015
Q4 		$943K Buy
29,838
+4,608
+18% +$163K 0.12% 285
2015
Q3 		$868K Sell
25,230
-13,524
-35% -$409K 0.14% 274
2015
Q2 		$1.22M Buy
+38,754
New +$1.14M 0.14% 271

Other funds holding MRTX

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

EAM Investors's MRTX Position: Q1 2021 in Review

EAM Investors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 11,552 shares — an estimated $2.54M sold.

EAM Investors first reported a position in MRTX in Q2 2015 and held it in 13 quarters. The position peaked at $4.91M in Q2 2018. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • EAM Investors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • EAM Investors sold 11,552 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.54M.
  • EAM Investors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 13 quarters.
  • EAM Investors's Mirati Therapeutics, Inc. Common Stock position peaked at $4.91M in Q2 2018.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.